Bosentan is a ______. - ERA , Selexipag brand name - Uptrevi , Selexipag is a _______. - PRA , Riociguat is a _______. - sGCS , ________ and sildenafil are contraindicated. - Riociguat , _______ and _______ are teratogenic. - ERA and Riociguat, _________ and ________ combo therapy is recommended for initial therapy for low/intermediate risk PAH.  - ERA, PDE-5i, ___________ has a risk of hepatotoxicity. - Bosentan , ___________ is the cornerstone of treatment for severe PAH. - PCA infusions/inhaled , Risks of PCA therapy - Infection, pump malfunction, hypotension, Sildenafil brand name - Revatio , PAH WHO Group - 1, Epoprostenol and Treprostinil are _____.  - prostacyclins analogues , ERA with mortality benefit - Macitentan , Side effects of PCA - hypotension, jaw pain, headache , _______, ________, and ________ can be started for initial therapy of high risk PAH. - ERA, PDE-5i, and PCA , _________ is used to diagnosis PAH. - Right heart catherization , Adjunctive therapy for PAH includes_________. - Diuretics, contraception , Routes for PCA - Inhaled, IV, oral, subq , Major pathways for PAH treatment - Endothelin, nitric oxide, and prostacyclin,

PAH Lecture

Одштампај
Угради

Табела

Визуелни стил

Поставке

Промени шаблон

Врати аутоматски сачувано: ?